<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20220413054530N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-05-02</date_registration>
      <primary_sponsor>Gonabad University of Medical Sciences</primary_sponsor>
      <public_title>The effect of ear acupressure on diabetes</public_title>
      <acronym></acronym>
      <scientific_title>The effect of ear acupressure in comparison with sham control on neuropathy symptoms and quality of life in patients with type 2 diabetes</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-05-10</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>70</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/62955</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Used, Assignment: Parallel, Purpose: Supportive, Randomization description: In this study, patients with diabetes referred to a special clinic in Boshrouyeh, affiliated to Birjand University of Medical Sciences, will be selected by an accessible and purposeful method based on inclusion criteria and then randomly divided into four groups of intervention and control by blocks of size 4. In this way, a list of 6 expected blocks (AABB, ABAB, BABA, ABBA, BAAB, BBAA) has been prepared and by assigning a number to each block (from 1 to 6) by throwing the dice, the blocks are randomly selected and the necessary allocation is made. This process will continue until the sample size is completed. (A for the experimental group and B for the control group), Blinding description: In this study, participants will be randomly assigned to one of two control or test groups and will be unaware of which group they are in. For blinding in the control group, ear acupressure labels similar to the experimental group will be used, with the difference that in the control group, these labels will be used in places that will not have an effect on improving patients' neuropathy.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Diabetic neuropathy.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: For patients in this group, in addition to the patient's routine medical care for acupressure, pressure is applied to the labels containing 5 plant seeds (which are used to form labels and the type of plant used has no effect on acupressure) located in the adaptive area of the legs in the ear. The external will be used for 1 minute (the pressure will be to the extent that the patient feels it but does not cause pain and discomfort) 3 times a day (every 8 hours) for 6 weeks by the patient after training. Intervention 2: Control group: In this group, in addition to the patient's routine medical care, pressure is applied to the labels containing 5 plant seeds located in the adaptive area of the heart (which has no effect on patients' neuropathy) in the outer ear for 1 minute, which is 3 times. It is performed around the clock (every 8 hours) for 6 weeks by the patient himself after training.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no more information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Ali mohammad ali nia</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No. 43; Farhangian building; behind Hazrat Khadijeh Mosque; Varzesh Boulevard</address>
        <city>Boshruoyeh</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>9781683641</zip>
        <telephone>+98 56 3278 1142</telephone>
        <email>a.mohammadnia69@gmail.com</email>
        <affiliation>Gonabad University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Ali Mohammd Ali nia</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No. 43; Farhangian building; behind Hazrat Khadijeh Mosque; Varzesh Boulevard</address>
        <city>boshrouyeh</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>9781683641</zip>
        <telephone>+98 56 3278 1142</telephone>
        <email>a.mohammadnia69@gmail.com</email>
        <affiliation>Gonabad University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patient willingness and having written informed consent to participate in the study
Get a minimum score of 6 on the Toronto Diabetic Neuropathy Questionnaire
Awareness and ability to speak and communicate to report the severity of clinical symptoms during the examination
Age between 18 to 60 years
Having a natural earlobe</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>60 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>History of disease or condition affecting neuropathy based on medical history and patient report
The presence of any known complication and other medical problem leads to pain
Existence of a lesion or skin problem in the area of the ear and the site of acupressure</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>G99.0</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Autonomic neuropathy in diseases classified elsewhere</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Other</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: For patients in this group, in addition to the patient's routine medical care for acupressure, pressure is applied to the labels containing 5 plant seeds (which are used to form labels and the type of plant used has no effect on acupressure) located in the adaptive area of the legs in the ear. The external will be used for 1 minute (the pressure will be to the extent that the patient feels it but does not cause pain and discomfort) 3 times a day (every 8 hours) for 6 weeks by the patient after training.</i_keyword>
      <i_keyword>Control group: In this group, in addition to the patient's routine medical care, pressure is applied to the labels containing 5 plant seeds located in the adaptive area of the heart (which has no effect on patients' neuropathy) in the outer ear for 1 minute, which is 3 times. It is performed around the clock (every 8 hours) for 6 weeks by the patient himself after training.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Symptoms of neuropathy include pain and sensory disturbances (including burning, numbness, tingling, weakness, muscle cramps). Timepoint: Beginning of the study (before the intervention) and after the intervention (six weeks after the intervention). Method of measurement: Neuropathy Symptom Score.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Quality of life. Timepoint: At the beginning of the study (before the intervention) and six weeks after the start of the study. Method of measurement: Neuropathy specific quality of life.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Gonabad University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-04-11</approval_date>
        <contact_name>Ethics Committee of Gonabad University of Medical Sciences</contact_name>
        <contact_address>Vice Chancellor for Research and Technology, Gonabad University of Medical Sciences, Asian Roadside, Gonabad - Khorasan Razavi Gonabad Razavi Khorasan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
